文献速递老年精神心境障碍

抑郁症状与淀粉样蛋白病理

Depressive Symptoms and Amyloid Pathology.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

该横断面分析汇集49项研究、9746名认知正常者和3023名轻度认知障碍者的数据,探讨抑郁症状与淀粉样蛋白病理的关联。认知正常者中抑郁症状与淀粉样蛋白病理无显著关联(OR 1.13),而轻度认知障碍者中抑郁症状与淀粉样蛋白病理可能性降低相关(OR 0.73)。

要点

  • 认知正常者中抑郁症状与淀粉样蛋白病理无显著关联(OR 1.13,95%CI 0.90-1.40,P=0.29)。
  • 轻度认知障碍者中抑郁症状与淀粉样蛋白病理可能性降低相关(OR 0.73,95%CI 0.61-0.89,P=0.001)。
  • 认知正常者中,APOE ε4非携带者伴抑郁症状者淀粉样蛋白病理频率较高(均差5.0%,95%CI 1.0-9.0,P=0.02)。

核心结论

  • 在认知正常者中,抑郁症状与淀粉样蛋白病理较高频率无一致关联;在轻度认知障碍者中,抑郁症状与淀粉样蛋白病理可能性降低相关。
  • 这些发现未受年龄、性别或教育程度影响;晚年抑郁症状可能通常由淀粉样蛋白沉积以外的机制所致。

研究设计与样本

  • 横断面分析,使用淀粉样蛋白生物标志物研究数据汇集计划的数据,汇集49项研究、人口学和记忆门诊研究的数据并统一化。
  • 纳入9746名认知正常者和3023名轻度认知障碍者,年龄34至100岁,具备淀粉样蛋白生物标志物、抑郁症状和年龄数据;数据分析时间为2022年12月至2024年2月。

主要发现

  • 认知正常者(平均[SD]年龄68.6[8.9]岁;5664[58.2%]女性;3002[34.0%]APOE ε4携带者;937[9.6%]有抑郁症状;2648[27.2%]有淀粉样蛋白病理)中,抑郁症状与淀粉样蛋白病理无显著关联(OR 1.13;95%CI 0.90-1.40;P=0.29)。
  • 轻度认知障碍者(平均[SD]年龄70.2[8.7]岁;1481[49.0%]女性;1046[44.8%]APOE ε4携带者;824[27.3%]有抑郁症状;1668[55.8%]有淀粉样蛋白病理)中,抑郁症状与淀粉样蛋白病理可能性降低相关(OR 0.73;95%CI 0.61-0.89;P=0.001)。
  • 认知正常者中,抑郁症状与APOE ε4非携带者淀粉样蛋白病理频率较高相关(均差5.0%;95%CI 1.0-9.0;P=0.02),APOE ε4携带者中无此关联;轻度认知障碍者中未见此情况。

关键数值与推荐

  • 淀粉样蛋白病理通过脑脊液淀粉样蛋白β1-42水平或淀粉样蛋白正电子发射断层扫描确定存在或不存在。
  • 抑郁症状通过经验证的抑郁评定量表评分、当前临床抑郁诊断证据或自我报告的抑郁症状确定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Depressive symptoms are associated with cognitive decline in older individuals. Uncertainty about underlying mechanisms hampers diagnostic and therapeutic efforts. This large-scale study aimed to elucidate the association between depressive symptoms and amyloid pathology. OBJECTIVE: To examine the association between depressive symptoms and amyloid pathology and its dependency on age, sex, education, and APOE genotype in older individuals without dementia. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analyses were performed using data from the Amyloid Biomarker Study data pooling initiative. Data from 49 research, population-based, and memory clinic studies were pooled and harmonized. The Amyloid Biomarker Study has been collecting data since 2012 and data collection is ongoing. At the time of analysis, 95 centers were included in the Amyloid Biomarker Study. The study included 9746 individuals with normal cognition (NC) and 3023 participants with mild cognitive impairment (MCI) aged between 34 and 100 years for whom data on amyloid biomarkers, presence of depressive symptoms, and age were available. Data were analyzed from December 2022 to February 2024. MAIN OUTCOMES AND MEASURES: Amyloid-β1-42 levels in cerebrospinal fluid or amyloid positron emission tomography scans were used to determine presence or absence of amyloid pathology. Presence of depressive symptoms was determined on the basis of validated depression rating scale scores, evidence of a current clinical diagnosis of depression, or self-reported depressive symptoms. RESULTS: In individuals with NC (mean [SD] age, 68.6 [8.9] years; 5664 [58.2%] female; 3002 [34.0%] APOE ε4 carriers; 937 [9.6%] had depressive symptoms; 2648 [27.2%] had amyloid pathology), the presence of depressive symptoms was not associated with amyloid pathology (odds ratio [OR], 1.13; 95% CI, 0.90-1.40; P = .29). In individuals with MCI (mean [SD] age, 70.2 [8.7] years; 1481 [49.0%] female; 1046 [44.8%] APOE ε4 carriers; 824 [27.3%] had depressive symptoms; 1668 [55.8%] had amyloid pathology), the presence of depressive symptoms was associated with a lower likelihood of amyloid pathology (OR, 0.73; 95% CI 0.61-0.89; P = .001). When considering subgroup effects, in individuals with NC, the presence of depressive symptoms was associated with a higher frequency of amyloid pathology in APOE ε4 noncarriers (mean difference, 5.0%; 95% CI 1.0-9.0; P = .02) but not in APOE ε4 carriers. This was not the case in individuals with MCI. CONCLUSIONS AND RELEVANCE: Depressive symptoms were not consistently associated with a higher frequency of amyloid pathology in participants with NC and were associated with a lower likelihood of amyloid pathology in participants with MCI. These findings were not influenced by age, sex, or education level. Mechanisms other than amyloid accumulation may commonly underlie depressive symptoms in late life.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wiels WA, Oomens JE, Engelborghs S, et al. Depressive Symptoms and Amyloid Pathology. JAMA Psychiatry. 2025. PMID: 39841452. doi:10.1001/jamapsychiatry.2024.4305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。